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ABSTRACT
FRAXA is one of a number of fragile sites in
human chromosomes that are induced by agents
like fluorodeoxyuridine (FdU) that affect intracellular
thymidylate levels. FRAXA coincides with a 4200
CGG CCG repeat tract in the 5’ UTR of the FMR1
gene, and alleles prone to fragility are associated
with Fragile X (FX) syndrome, one of the leading
genetic causes of intellectual disability. Using
siRNA depletion, we show that ATR is involved
in protecting the genome against FdU-induced
chromosome fragility. We also show that FdU
increases the number of c-H2AX foci seen in both
normal and patient cells and increases the fre-
quency with which the FMR1 gene colocalizes with
these foci in patient cells. In the presence of FdU
and KU55933, an ATM inhibitor, the incidence of
chromosome fragility is reduced, suggesting that
ATM contributes to FdU-induced chromosome
fragility. Since both ATR and ATM are involved in
preventing aphidicolin-sensitive fragile sites, our
data suggest that the lesions responsible for
aphidicolin-induced and FdU-induced fragile sites
differ. FRAXA also displays a second form of
chromosome fragility in absence of FdU, which our
data suggest is normally prevented by an ATM-
dependent process.
INTRODUCTION
Fragile X syndrome (FXS) is the most common heritable
cause of intellectual disability. The disorder is named
for a fragile site on the X chromosome that is seen
when patient cells are treated with agents like folate or
5-ﬂuorodeoxyuridine (FdU) that aﬀect a key enzyme in
the pyrimidine biosynthetic pathway, thymidylate
synthase (1,2). This causes a nucleotide pool imbalance
thereby slowing replication and perhaps requiring repair
to remove misincorporated bases. The fragile site appears
as a gap, constriction or break in metaphase chromo-
somes. The Fragile X fragile site is also known as
FRAXA (Fragile site on X chromosome, site A).
FRAXA is coincident with a stretch of 4200
CGG CCG-repeats in the 50 UTR of the FMR1 gene
that is responsible for FXS (3,4). Alleles with this
number of repeats arise from an increase in the number
of repeats on maternal transmission of an allele with
55–200 repeats. The relationship between this repeat
expansion and chromosome fragility is unknown.
The sequence basis of six other folate-sensitive fragile
sites in the human genome, FRAXE, FRAXF, FRA10A,
FRA11A, FRA11B, FRA12A and FRA16A, have so far
been determined. In all instances, the responsible sequence
is also a long CGG CCG-repeat tract (5–10). FRAXA is
a frequent translocation breakpoint in rodent-human
somatic hybrids (4,11). FRA11B, is associated with dele-
tion of the telomeric end of long arm of chromosome 11 in
a number of cases of Jacobsen Syndrome (12,13).
More than 110 other fragile sites are found in human
genomes, many of which are common translocation
breakpoints associated with diﬀerent forms of cancer.
Many of these sites are induced by aphidicolin (APC)
and 13 such sites have been studied so far at the sequence
level. They are all associated with hundreds of kilobases or
even megabases of DNA with no particularly distinctive
sequences (5,14–27). In the case of FRA3B, the most
active APC-sensitive fragile site, breakage is seen in mul-
tiple places throughout a 4-Mb region and it has been
suggested that no single sequence is responsible (28).
Agents that induce chromosome fragility all share with
folate-stress the potential to interfere with DNA
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polymerase a, d and e (29,30). At high concentrations
these compounds may also aﬀect DNA repair.
ATR and ATM are kinases responsible for the initiation
and management of the DNA damage response (DDR)
in mammals (31,32). Depending on the type of DNA
damage, one or both of these enzymes are activated. The
activated protein then initiates a kinase cascade that acti-
vates key downstream eﬀectors of the DDR. The ATR-
pathway is thought to be involved primarily in the cellular
response to stalled replication forks and bulky DNA
lesions that block DNA synthesis, while the ATM path-
way is thought to respond primarily to double-strand
breaks although some cross-talk between these pathways
is apparent. Both ATR and ATM have been shown to
protect the genome against APC-sensitive chromosome
fragility (19,33–38).
Here we describe our analysis of FRAXA. Our
data show that, as with the APC-sensitive sites, the
ATR-pathway is involved in preventing FdU-sensitive
chromosome fragility at FRAXA. KU55933, an inhibitor
speciﬁc for ATM, reduces FdU-induced chromosome fra-
gility. This suggests that a KU55933-sensitive enzyme,
most likely ATM, is actually responsible for the genera-
tion of the fragile site. In addition, we show here that the
Fragile X alleles exhibit a second form of fragility that is
FdU-independent and that ATM is most likely responsi-
ble for preventing this form of chromosome fragility. This
suggests that FRAXA diﬀers in important ways from the
APC-sensitive fragile sites and that FXS alleles form at
least two diﬀerent kinds of DNA lesions that gives rise
to chromosome fragility, one that is normally repaired
by ATR but not by ATM, and one that is repaired
by ATM.
MATERIALS AND METHODS
Cell lines and reagents
Two male FX lymphoblastoid cells lines (GM03200B and
GM07294), two normal lymphoblastoid cell lines
(GM06895 and GM06865), an Ataxia Telangiectasia cell
line (GM00719), a Seckel disease cell line (GM09703) and
FXS ﬁbroblasts (GM05848) were obtained from the
Coriell Institute for Medical Research (Camden, NJ).
The male FX lymphoblastoid cell line LL4118 was
established by Dr Esterina Pascale (CNR, Rome, Italy;
personal communication). The repeat numbers in all
four FX patient cell lines was  500–700 (4,39).
Lymphoblastoid cells were grown in RPMI 1640 supple-
mented with 10% FBS and 1  antibiotic–antimycotic
liquid consisting of penicillin, streptomycin and fungisone
(Invitrogen, Carlsbad, CA). Fibroblasts were grown in
DMEM (Invitrogen) supplemented with 10% FBS and
1  antibiotic-antimycotic liquid. The BAC clones
RP11-80F18 containing the Xq27.1 region centromeric
to the FMR1 gene at Xq27.3, RP11-383P16 containing
the Xq27–28 region and RP11-402H20 which contains
Xq28 derived sequences were obtained from the Chil-
dren’s Hospital Oakland Research Institute (CHORI;
Oakland, CA). A probe corresponding to chromosome
4q11-12 (RP11-535c7) was used as a negative control
(CHORI). Previously described siRNA to ATR and
their controls (34) were purchased from the Dharmacon
subsidiary of Thermo Fisher Scientiﬁc (Lafayette, CO).
Antibody to CHK2 phosphorylated at T68 (sc-16297-R)
was purchased from Santa Cruz Biotechnology Inc (Santa
Cruz, CA), antibodies to CHK1 phosphorylated at S317
(#2346) or S345 (#2341) and p53 phosphorylated at S15
(#9286) were purchased from Cell Signalling (Danvers,
MA), antibody to RPA2/p34 (MS-691) was from
Thermo Scientiﬁc (Waltham, MA), g-H2AX (ab18311)
was from Abcam (Cambridge, MA). UCN-01 (7-hydro-
xystaurosporine) was a kind gift of Dr Kondapaka (NCI,
NIH). The ATM inhibitor KU55933 was from Calbio-
chem (San Diego, CA). Remaining reagents were pur-
chased from Sigma-Aldrich (St Louis, MO) unless
otherwise speciﬁed.
Fragile site analysis
Transfection of siRNAs was carried out using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instruction. Fibroblasts were grown for several
hours in a six-well plate with 2ml of medium without
antibiotics. The cells were harvested after a total of 96h.
Fragile X expression was examined in cells treated with
0.1mMo r1mM FdU for 16h. The depletion of ATR was
conﬁrmed by western blotting. KU55933 and UCN-01
were used where indicated at 10mM and 100nM respec-
tively. Cells were then treated for 1–6h with 50ng/ml col-
cemid. Metaphase chromosome spreads were prepared
and the fragile sites visualized either on Giemsa stained
chromosomes or by FISH using standard procedures.
FISH probes were prepared from the BAC clones by label-
ing using a nick-translation kit from Roche (Basel,
Switzerland) and tetramethyl-Rhodamine-5-dUTP. BAC
clones RP11-383P16 andRP11-402H20, containing
sequences telomeric to FRAXA, were used as probes for
FRAXA fragility. The BAC RP11-535c7 was used as a
negative control. In the FISH experiments, chromosomes
were counterstained with 4,6-diamidino-2-phenylindole-
dihydrochroride (DAPI) and the spreads visualized by
epiﬂuorescence microscopy. At least 50 metaphases were
examined for each experiment and each experiment was
done in triplicate.
Western blotting
Analysis of the activation status of various proteins
involved in the cellular response to DNA damage were
examined in total protein extracts prepared from cells
grown under the same conditions as those used to examine
the fragile site. Preparation of extracts, and the SDS–gel
electrophoresis and western blotting of these extracts was
carried out using standard procedures. Detection was
done using an ECL
TM kit (GE Healthcare, Piscataway,
NJ), according to the manufacturer’s instructions.
Immunocytochemistry and interphase FISH
Lymphoblastoid cells were grown with or without 1mM
FdU for 18h. After treatment, 2 10
5cells were deposited
on positively charged glass slides by spinning at 80g for
4386 Nucleic Acids Research, 2009, Vol. 37,No. 135min at RT in a cytospin centrifuge. Slides were ﬁxed with
methanol at  208C for 30min and then rinsed with
cold acetone. Slides were stained with mouse monoclonal
anti-g-H2AX antibody (1/400 dilution) followed by
Alexa-488-conjugated anti-mouse IgG (1/400 dilution,
Molecular probes, Eugene, OR). Cells were then ﬁxed
with 50mM ethylene glycol-bis(succinic acid N-hydroxy-
succinimide ester). Probe hybridization was carried out on
ﬁxed cells as previously described (40). Brieﬂy, DNA was
denatured using 0.07M NaOH at room temperature for
3min. The biotin-labeled FMR1 probe was hybridized
at 378C overnight, followed by washing in pre-warmed
50% formamide/2  SSC and pre-warmed 0.1  SSC.
The FMR1 probe was detected by Alexa-555-conjugated
anti-streptavidin antibody (1/400 dilution, Molecular
probes, Eugene, OR). DNA was counterstained with
DAPI. The slides were then visualized using an Olympus
ﬂuorescent microscope (Olympus America Inc. Melville,
NY). One hundred cells were counted for each experiment
for a total of 200 cells/treatment.
Detection of g-H2AX without FMR1 colocalization
was done by ﬁxing cells with 2% paraformaldehyde for
20min at RT and depositing 2 10
5cells of these ﬁxed
cells on positively charged glass slides by spinning at
80g for 5min at RT in a cytospin centrifuge. Cells were
permeabilized with 70% ethanol at 48C for 30min and
treated with mouse monoclonal anti-g-H2AX (1/400 dilu-
tion) as described above. The DNA was counterstained
with propidium iodide (PI). Laser scanning confocal
microscopy was performed with a Nikon PCM 2000
(Nikon, Inc., Augusta, GA). Two hundreds cells were
counted for each experiment using previously published
criteria (41).
RESULTS
FdU and APC-treatment have similar effects on the
activation of DDR proteins
Activation of the ATM and ATR DDR pathways leads to
phosphorylation of a number of proteins downstream of
these kinases. In order to test which of these proteins are
activated in conditions that result in FRAXA fragility, we
carried out western blotting on protein extracts prepared
from FdU-treated cells from both aﬀected and unaﬀected
individuals using antibodies for the phosphorylated forms
of various DDR proteins. Activation with FdU was com-
pared to that seen with APC, etoposide, which induces
DNA double strand breaks, and hydroxyurea (HU), an
inhibitor of ribonucleotide reductase that results in repli-
cation fork stalling.
The results for two-patient cell lines and an age-
matched control are shown in Figure 1. FdU-treatment
caused increased phosphorylation of CHK1 at S317 and
S345 even at concentrations 100-fold lower than that used
to visualize the FX fragile site (Figure 1 and data not
shown). Agents like etoposide and HU increased phos-
phorylation of CHK2 at threonine 68 and p53 at serine
15 (Figure 1). However, little or no phosphorylation of
CHK2 or RPA2 was seen with either APC or FdU. No
phosphorylation of p53 was seen in GM07294 although a
small amount was seen in GM0032B (Figure 1), and two
other cell lines in the presence of FdU (data not shown).
GM07294 also shows less CHK1 phosphorylation than
GM0032B. It is thus possible that the DDR is less
eﬃciently induced in this cell line. We thus cannot exclude
the possibility that some phosphorylation of p53 occurs in
this cell line that is below the sensitivity of our assay. Our
results diﬀer somewhat from previously published
data where APC was shown to cause signiﬁcant phosphor-
ylation of Chk2, p53 and RPA2 (36). These diﬀerences
could be due to diﬀerences in the growth conditions or
to genetic variation in the DDR in the human population.
Nevertheless, our results demonstrate that in our cell lines,
the DDR response to FdU and APC are similar and that
the CHK1 pathway, rather than the typical DSB-response
pathway that involves CHK2, is the major pathway acti-
vated in response to both APC and FdU.
Knockdown of ATR or UCN-01 treatment increases
FRAXA expression
In order to assess the role of diﬀerent DDR pathways on
expression of the FX fragile site more directly, we ﬁrst
treated FX ﬁbroblasts with siRNAs targeted to ATR
and examined the frequency of chromosome breaks and
rearrangements at the FMR1 locus. Fibroblasts were used
rather than lymphoblastoid cells because of their higher
transfection eﬃciency. The incidence of breaks and rear-
rangements was compared to that seen without either
FdU or siRNAs to ATR, with FdU alone and when
ATR siRNAs were used in combination with FdU. No
chromosome fragility was seen in normal cells under any
of these conditions or in untreated patient cells. In con-
trast, ATR knockdown, with or without FdU treatment,
Figure 1. Activation of DNA damage signaling proteins by FdU treat-
ment. Western blots of extracts from an unaﬀected cell line, GM06895
and 2 FX cell lines, GM07924 and GM03200B, treated with various
DNA damaging agents were probed with the indicated antibodies.
Etoposide (Et) was used at 68mM for 2h. Hydroxyurea (HU) was
used at a concentration of 2mM for 24h. Fluorodeoxyuridine, abbre-
viated in this ﬁgure as FU for reasons of space, was used at 1mM for
18h. Aphidicolin, indicated here by the abbreviation AP, was used at
0.4mM for 24h. Note that the same gel was used for the detection of
RPA2 and CHK1 and so the same b-actin control applies. The b-actin
data for both experiments is shown beneath the CHK1 data.
Nucleic Acids Research, 2009,Vol.37, No. 13 4387resulted in chromosome fragility in patient cells that was
detected using probes containing sequences telomeric to
FMR1 (Figure 2). Similar results were obtained with
both RP11-383P16 and RP11-402H20, which contain
sequences from Xq27-28 and Xq28, respectively. No fra-
gility was seen when the BAC, RP11-80F18, which con-
tains sequences centromeric to FRAXA, was used a probe
(data not shown).
In addition to more typical fragile sites (Figure 3A), a
small number of unusual derivative chromosomes were
seen, including those containing duplications of the
Xq27–28 region or two sister chromatids joined by
three copies of the Xq27–28 region (Figure 3B–D).
These chromosomes, which constituted <10% of the
derivative chromosomes, are reminiscent of the products
of breakage-fusion-bridge (BFB) cycles ﬁrst described by
Barbara McClintock (42), and subsequently demonstrated
for a number of APC-inducible fragile sites (43,44). A
similar increase in chromosome fragility and chromosome
abnormalities was seen when patient cells were treated
with UCN-01, a strong inhibitor of CHK1 (Figure 4A).
KU55933 increases chromosome breakage at FRAXA but
reduces the incidence of FdU-dependent FRAXA fragility
We also examined the eﬀect of the ATM inhibitor
KU55933 on chromosome fragility at FRAXA. Unlike
many commonly used inhibitors of the phosphatidylinosi-
tol 30-kinase-related kinase (PIKK) family to which ATM
and ATR belong, KU55933 is considered a relatively spe-
ciﬁc inhibitor of ATM (45). It is 100 times more active
against ATM than other PIKK family members, and does
not inhibit ATR, the kinase to which ATM is most simi-
lar, even when used at 10 times the concentration we used
here (45). Normal cells show no increase in chromosome
fragility at FMR1 in the presence of KU55933 (data not
shown). In the absence of FdU, KU55933 caused an
increase in fragile site expression in FX cells. However,
unlike what was seen with ATR depletion or UCN-01
treatment, KU55933 did not exacerbate the eﬀect of
Figure 3. Representative metaphases seen in FX lymphoblasts after
treatment with 1mM FdU and/or 100nM UCN-01. (A) X chromosome
showing breakage of both sister chromatids. (B) FISH showing X chro-
mosome in which one chromatid shows what appears to be a partial
duplication of part of the FRAXA region. (C) X chromosome in which
one chromatid has lost the FRAXA region and the other has two
copies of that region. (D) X chromosome in which the end of the
long arm of the sister chromatids are linked by three copies of the
FRAXA region.
Figure 4. Eﬀect of CHK1 and ATM inhibition on fragile site expres-
sion at FRAXA in FX lymphoblastoid cells. (A) FX lymphoblastoid
cells treated with UCN-01 with and without FdU. (B) FX lymphoblas-
toid cells treated with KU55933 with and without FdU. The data
shows the average of three independent experiments for each cell line.
Unt: untreated or vehicle only.
Figure 2. Eﬀect of siRNA knockdown of ATR on fragile site expres-
sion at FRAXA in FX ﬁbroblasts. The level of FRAXA expression in
FX ﬁbroblasts (GM05848) with and without ATR depletion in the
presence and absence of FdU. The data shows the average of three
independent experiments. C: control.
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FRAXA when treated with both FdU and KU55933
was much lower than what was seen in FdU alone
(Figure 4B). The fact that ATR depletion and KU55933
treatment have such diﬀerent eﬀects rules out an oﬀ-target
eﬀect of KU55933 on ATR and lends support to the idea
that ATM is in fact the kinase most likely to be aﬀected by
the inhibitor. Our data would be consistent with the idea
that some ATR-independent DDR pathway, most likely
one mediated by ATM, contributes to FdU-sensitive chro-
mosome fragility but protects against fragility arising
during cell growth in the absence of FdU. Activation of
ATM as well as ATR by FdU would be consistent with
previous reports of activation of both kinases by thymi-
dine-stress, which like FdU causes a nucleotide pool
imbalance (46) and also induces FRAXA chromosome
fragility (47).
c-H2AX colocalizes with the FMR1 locus in response
to FdU treatment
APC-inducible fragile sites colocalize with the g-H2AX
foci that normally form at double strand breaks (DSBs)
and double-strand ends found at stalled replication forks
(41). In order to test if the same is true of FRAXA, we
carried out in situ hybridization with a FMR1 BAC clone
in combination with immunoﬂuorescence with an antibody
to g-H2AX. In the absence of FdU, an average of  1
g-H2AX focus/cell was seen in both normal and FXS
cells (Figure 5). Colocalization of these foci with the
FMR1 locus probe was seen in a small percentage of
untreated normal and FX cells (Figure 5). This may be
related to the presence of the common fragile site,
FRAXD, in this region (48) or to some inherent problem
present at this locus even in normal alleles. FdU-treatment
increased the number of g-H2AX foci in both normal and
FXS cells to  4–5/cell. This contrasts with the much larger
number of foci seen when cells are treated with enough
APC to induce fragility at common fragile sites (37).
Thus, despite the prolonged treatment with this FdU
dosage, large-scale DNA damage is not apparent.
However, this treatment did increase the number of cells
in which g-H2AX foci colocalized with probes containing
FRAXA (Figure 5). In particular, the number of cells in
which colocalization was observed was signiﬁcantly higher
in patient cells than in cells from unaﬀected individuals and
is of the same order of magnitude as the number of fragile
sites seen under the same conditions (Figure 5). This lends
support to the idea that the FX allele is associated with
the formation of DSBs or related structures in response
to FdU. Since thymidine-stress does not produce DSBs
(46), a structure other than a frank DSB is perhaps more
likely.
Figure 5. Colocalization of FX alleles with g-H2AX foci in the presence of FdU. Immunocytochemistry combined with FISH was used to examine
the colocalization of g-H2AX foci and the FMR1gene in normal (GM06865 and GM06895) and FXS lymphoblastoid cells (GM07294 and
GM03200B) treated with or without 1mM FdU for 18h. (A) Representative images of g-H2AX (green) and FMR1 (red) stained cells. (B)
Proportion of cells in which g-H2AX and FMR1 colocalize. The data shows the average of two independent experiments in which a 100 FMR1
signals were counted for each experiment. Error bars signify standard deviation. Statistical analysis was carried out using Fishers exact test. A single
asterisk indicates a P-value <0.01, while a double asterisk indicates a P-value <0.005. Note that the X chromosome tends to be located at the nuclear
periphery (54). This can make it seem in some cases as if the FMR1 signal is located outside of the nucleus.
Nucleic Acids Research, 2009,Vol.37, No. 13 4389The basis of the FdU-induced foci seen in both normal
and patient cells is currently unknown. The simplest expla-
nation is that these foci represent regions of the human
genome that, like FX alleles, contain long CGG CCG-
repeat tracts or related sequences with similar biological
properties. In a cell line, GM09703, that has reduced
levels of ATR and is deﬁcient in the ATR pathway (49),
no increase in the number of g-H2AX foci was seen
in response to FdU (Figure 6). This suggests that the
ATR-pathway is responsible for the generation of the
common FdU-induced g-H2AX foci. It remains to be
seen whether ATR is also responsible for the foci that
colocalize with FRAXA. No change in the number of
FdU-induced foci was seen in AT-cells or in normal
cells treated with KU55933 (Figure 6). The latter result
would be consistent with the eﬀect of KU55933 being
ATM-speciﬁc and these data taken together suggest that
the common FdU-induced g-H2AX foci are ATM-
independent.
DISCUSSION
To assess the similarities between APC-inducible and FdU
inducible fragile sites, we have examined the activation
of diﬀerent DNA damage response pathways and
chromosome fragility at FRAXA after FdU treatment.
Our data demonstrate that as with APC treatment, FdU
causes phosphorylation of CHK1 but, little, if any CHK2,
RPA2 or p53 activation. FdU also increases the colocali-
zation of the FMR1 locus with g-H2AX foci (Figure 5),
analogous to what is seen with APC-sensitive fragile sites
(37). Thus, in some ways APC and FdU have grossly sim-
ilar eﬀects on human cells and their respective fragile sites.
However, important diﬀerences between the APC and
FdU response are also seen. ATR knockdown and the
use of KU55933, an ATM inhibitor, have opposite eﬀects
on FdU-induced FRAXA chromosome fragility, increas-
ing and decreasing FRAXA expression respectively
(Figures 2 and 4B). Since ATM and ATR are both
involved in protecting the genome from APC-sensitive
chromosome fragility (37), our data suggest that the
basis of the FdU-sensitive FX fragile site is diﬀerent
from that of the APC-sensitive fragile sites.
Since ATR is activated primarily in response to stalled
replication forks and bulky DNA lesions that block DNA
polymerase, and CGG CCG-repeats form non-canonical
structures like hairpins and tetraplexes that block DNA
synthesis in vitro (50) and are thought to cause replication
fork stalling in bacteria (51) and yeast (52), it is tempting
to think that these sorts of structures may be responsible
for the problems that give rise to the FdU-induced
FRAXA chromosome fragility. In this view, illustrated
in Figure 7A, the nucleotide pool imbalance resulting
from FdU treatment slows replication through the
repeat region, perhaps causing uncoupling of leading
and lagging strand DNA synthesis. This may create a
greater opportunity for structures like hairpins and
Figure 6. The FdU-induced common g-H2AX foci are dependent on
ATR not ATM. GM06865 with and without ATM inhibitor (ATMi),
an AT cell line, GM00719, and an ATR-deﬁcient cell line, GM09703
were examined for the presence of FdU-induced g-H2AX foci
after growth with or without FdU as indicated. (A) shows representa-
tive ﬁelds obtained for each condition. (B) shows the combined data
for two independent experiments in which a total of 400 nuclei
were counted for each condition. The error bars indicate standard
deviations.
Figure 7. Comparison of models for FRAXA and APC-inducible chro-
mosome fragility. (A) In the presence of FdU, a lesion arises in the
FMR1 gene in FXS cells that result in activation of ATM and ATR.
ATR activation results in the lesion being successfully repaired, but
ATM activation can lead to chromosome fragility. In the absence
of FdU, a second type of chromosome fragility is seen, one that is
normally resolved by ATM. In the absence of ATM, an as yet uni-
dentiﬁed DNA damage response pathway is used instead and this leads
to the production of a fragile site. (B) A model for APC-inducible
fragile sites based on the data of Ozeri-Galai et al. (37). In the case
of these fragile sites, a lesion of some sort arises in the presence of
APC. ATR is primarily responsible for dealing with this lesion, but in
the absence of ATR, ATM can substitute for ATR. However, when
both ATR and ATM are depleted, an error-prone mechanism is used
to deal with the problem resulting in the formation of a fragile site.
It is unclear how these three types of fragile site diﬀer at the molecular
level. For this reason the responsible lesion is indicated by diﬀerent
colored question marks.
4390 Nucleic Acids Research, 2009, Vol. 37,No. 13tetraplexes to form that block DNA synthesis. The nucleo-
tide pool imbalance may also lead to the misincorporation
of bases that would then need to be excised. Since ATR
depletion exacerbates FdU-sensitive chromosome fragility
while the ATM inhibitor reduces it, it may be that ATM
and ATR normally compete for the repair of the underly-
ing lesion. When ATR is recruited to the lesion, it is
able to prevent the generation of a fragile site. However,
when ATM is involved, attempts to repair the lesion lead
to chromosome fragility. ATM inhibition may reduce
chromosome fragility by allowing more ATR-dependent
repair to take place.
Since the ATM inhibitor does increase chromosome
fragility, albeit of a type that is not exacerbated by
FdU, there is apparently also a previously unappreciated
FdU-independent form of chromosome fragility at
FRAXA. The basis of this fragility is unknown.
However, the presence at FRAXA of both ATR-sensitive
and lesions that may be sensitive to ATM is of interest
given the other ATR and ATM-sensitive events that occur
in long CGG CCG-repeat tracts. We have shown that a
mouse model with a long CGG CCG-repeat tract in the
murine Fmr1 gene shows two types of repeat expansion,
one that is ATR-sensitive and one that is ATM-sensitive
[(53) and manuscript in preparation]. These data would be
consistent with the idea that long CGG CCG-repeats
cause at least two diﬀerent kinds of DNA lesions and
that failure to resolve or repair them appropriately can
lead to chromosome fragility and/or repeat expansion.
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